Endpoints should map to indication-specific biology (e.g., AD: Aβ/tau and synaptic measures; PD: dopaminergic function; MS: myelination) alongside cross-cutting metrics (mitochondrial/oxidative stress, lipidomics, inflammatory signaling, barrier integrity where applicable, and network activity via multielectrode array (MEA). Here, MAPT is linked to Alzheimer disease.